N-acetyltransferase 2 Genotype in Colorectal Cancer and Selective Gene Retention in Cancers with Chromosome 8p Deletions

Overview

Journal Gut

Specialty Gastroenterology

Date 1997 Aug 1

PMID 9301503

Citations 13

Authors

A L Hubbard

D J Harrison

C Moyes

A H Wyllie

C Cunningham

E Mannion

C A Smith

Affiliations

Soon will be listed here.

Abstract

Background: Genetic polymorphisms in N-acetyltransferase (NAT2) can change the normally fast acetylation of substrates to slow acetylation, and have been associated with the development of some cancers. The NAT2 locus may also suffer dysregulation during cancer progression, as the gene resides on chromosome 8p22, a region which is frequently deleted in colorectal cancer.

Subjects And Methods: A polymerase chain reaction based method was used to determine NAT2 genotype in 275 patients with colon cancer and 343 normal control DNAs. Within the cancer group, 65 cases known to contain deletions in chromosome 8p were examined for loss of heterozygosity at the NAT2 locus.

Results: Overall, there was no statistical difference in frequency or distribution of NAT2 alleles and genotype between colon cancer and control groups. There was a significant association between the slow acetylation genotype and early age of onset. NAT2 genotype did not vary with other clinical features of colon cancer, which included Dukes's stage, site of tumour, and sex. Of 48 informative cases, only three (6%) showed loss of heterozygosity, indicating that the NAT2 locus is not commonly deleted in colorectal cancer. This suggests that NAT2 is retained during the process of allele loss possibly because of its proximity to a gene necessary for cell viability.

Conclusions: NAT2 does not play a major role in colorectal cancer risk, but may influence risk in some age groups. The nature of the loss of heterozygosity at the chromosome 8p site is complex and is worthy of further study.

Citing Articles

VDR Signaling via the Enzyme NAT2 Inhibits Colorectal Cancer Progression.

Zhu C, Wang Z, Cai J, Pan C, Lin S, Zhang Y Front Pharmacol. 2021; 12:727704.

PMID: 34867333 PMC: 8635240. DOI: 10.3389/fphar.2021.727704.

Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer.

Rendo V, Kundu S, Rameika N, Ljungstrom V, Svensson R, Palin K Sci Rep. 2021; 10(1):22436.

PMID: 33384440 PMC: 7775439. DOI: 10.1038/s41598-020-80288-z.

Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.

Sim E, Abuhammad A, Ryan A Br J Pharmacol. 2014; 171(11):2705-25.

PMID: 24467436 PMC: 4158862. DOI: 10.1111/bph.12598.

Polymorphisms of arylamine N-acetyltransferase2 and risk of lung and colorectal cancer.

Mahasneh A, Jubaili A, El Bateiha A, Al-Ghazo M, Matalka I, Malkawi M Genet Mol Biol. 2012; 35(4):725-33.

PMID: 23271930 PMC: 3526077. DOI: 10.1590/S1415-47572012005000074.

Absence of association between N-acetyltransferase 2 acetylator status and colorectal cancer susceptibility: based on evidence from 40 studies.

Zhang L, Zhou J, Wang J, Liang G, Li J, Zhu Y PLoS One. 2012; 7(3):e32425.

PMID: 22403658 PMC: 3293792. DOI: 10.1371/journal.pone.0032425.

References

Vatsis K, Weber W . Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys. 1993; 301(1):71-6. DOI: 10.1006/abbi.1993.1116. View

Rodriguez J, Kirlin W, Ferguson R, Doll M, Gray K, Rustan T . Human acetylator genotype: relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol. Arch Toxicol. 1993; 67(7):445-52. DOI: 10.1007/BF01969914. View

Hickman D, Sim E . N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem Pharmacol. 1991; 42(5):1007-14. DOI: 10.1016/0006-2952(91)90282-a. View

Abe M, Deguchi T, Suzuki T . The structure and characteristics of a fourth allele of polymorphic N-acetyltransferase gene found in the Japanese population. Biochem Biophys Res Commun. 1993; 191(3):811-6. DOI: 10.1006/bbrc.1993.1289. View

Zhong S, Wyllie A, Barnes D, Wolf C, Spurr N . Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis. 1993; 14(9):1821-4. DOI: 10.1093/carcin/14.9.1821. View

Grant D, Lottspeich F, Meyer U . Evidence for two closely related isozymes of arylamine N-acetyltransferase in human liver. FEBS Lett. 1989; 244(1):203-7. DOI: 10.1016/0014-5793(89)81193-7. View

Ladero J, Gonzalez J, Benitez J, Vargas E, Fernandez M, Baki W . Acetylator polymorphism in human colorectal carcinoma. Cancer Res. 1991; 51(8):2098-100. View

Yaremko M, Wasylyshyn M, Paulus K, Michelassi F, Westbrook C . Deletion mapping reveals two regions of chromosome 8 allele loss in colorectal carcinomas. Genes Chromosomes Cancer. 1994; 10(1):1-6. DOI: 10.1002/gcc.2870100102. View

Mommsen S, Barfod N, Aagaard J . N-Acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low-risk population. Carcinogenesis. 1985; 6(2):199-201. DOI: 10.1093/carcin/6.2.199. View

10.

Cantlay A, Lamb D, Gillooly M, Norrman J, Morrison D, Smith C . Association between the CYP1A1 gene polymorphism and susceptibility to emphysema and lung cancer. Clin Mol Pathol. 1995; 48(4):M210-4. PMC: 407965. DOI: 10.1136/mp.48.4.m210. View

11.

Grant D, Morike K, Eichelbaum M, Meyer U . Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest. 1990; 85(3):968-72. PMC: 296518. DOI: 10.1172/JCI114527. View

12.

Blum M, Demierre A, Grant D, Heim M, Meyer U . Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci U S A. 1991; 88(12):5237-41. PMC: 51847. DOI: 10.1073/pnas.88.12.5237. View

13.

Franke S, Klawitz I, Schnakenberg E, Rommel B, Van de Ven W, Bullerdiek J . Isolation and mapping of a cosmid clone containing the human NAT2 gene. Biochem Biophys Res Commun. 1994; 199(1):52-5. DOI: 10.1006/bbrc.1994.1192. View

14.

Sugimura T . Carcinogenicity of mutagenic heterocyclic amines formed during the cooking process. Mutat Res. 1985; 150(1-2):33-41. DOI: 10.1016/0027-5107(85)90098-3. View

15.

Farrington S, Cunningham C, Boyle S, Wyllie A, Dunlop M . Detailed physical and deletion mapping of 8p with isolation of YAC clones from tumour suppressor loci involved in colorectal cancer. Oncogene. 1996; 12(8):1803-8. View

16.

Smith G, Harrison D, East N, Rae F, Wolf H, Wolf C . Regulation of cytochrome P450 gene expression in human colon and breast tumour xenografts. Br J Cancer. 1993; 68(1):57-63. PMC: 1968301. DOI: 10.1038/bjc.1993.286. View

17.

Emi M, Fujiwara Y, Nakajima T, Tsuchiya E, Tsuda H, Hirohashi S . Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res. 1992; 52(19):5368-72. View

18.

Ilett K, Ingram D, Carpenter D, Teitel C, Lang N, Kadlubar F . Expression of monomorphic and polymorphic N-acetyltransferases in human colon. Biochem Pharmacol. 1994; 47(5):914-7. DOI: 10.1016/0006-2952(94)90493-6. View

19.

Risch A, Smelt V, Lane D, Stanley L, van der Slot W, Ward A . Arylamine N-acetyltransferase in erythrocytes of cystic fibrosis patients. Pharmacol Toxicol. 1996; 78(4):235-40. DOI: 10.1111/j.1600-0773.1996.tb00211.x. View

20.

Jacobs R . Role of dietary factors in cell replication and colon cancer. Am J Clin Nutr. 1988; 48(3 Suppl):775-9. DOI: 10.1093/ajcn/48.3.775. View